124 related articles for article (PubMed ID: 26281711)
1. Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide-Protease Fusions.
Sørensen HP; Xu P; Jiang L; Kromann-Hansen T; Jensen KJ; Huang M; Andreasen PA
J Mol Biol; 2015 Sep; 427(19):3110-22. PubMed ID: 26281711
[TBL] [Abstract][Full Text] [Related]
2. A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility.
Zhao B; Xu P; Jiang L; Paaske B; Kromann-Hansen T; Jensen JK; Sørensen HP; Liu Z; Nielsen JT; Christensen A; Hosseini M; Sørensen KK; Nielsen NC; Jensen KJ; Huang M; Andreasen PA
PLoS One; 2014; 9(12):e115872. PubMed ID: 25545505
[TBL] [Abstract][Full Text] [Related]
3. The binding mechanism of a peptidic cyclic serine protease inhibitor.
Jiang L; Svane AS; Sørensen HP; Jensen JK; Hosseini M; Chen Z; Weydert C; Nielsen JT; Christensen A; Yuan C; Jensen KJ; Nielsen NC; Malmendal A; Huang M; Andreasen PA
J Mol Biol; 2011 Sep; 412(2):235-50. PubMed ID: 21802428
[TBL] [Abstract][Full Text] [Related]
4. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs.
Hosseini M; Jiang L; Sørensen HP; Jensen JK; Christensen A; Fogh S; Yuan C; Andersen LM; Huang M; Andreasen PA; Jensen KJ
Mol Pharmacol; 2011 Oct; 80(4):585-97. PubMed ID: 21719463
[TBL] [Abstract][Full Text] [Related]
5. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
Andersen LM; Wind T; Hansen HD; Andreasen PA
Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
[TBL] [Abstract][Full Text] [Related]
6. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
Jiang L; Zhao B; Xu P; Sørensen HP; Jensen JK; Christensen A; Hosseini M; Nielsen NC; Jensen KJ; Andreasen PA; Huang M
Int J Biochem Cell Biol; 2015 May; 62():88-92. PubMed ID: 25744057
[TBL] [Abstract][Full Text] [Related]
7. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
[TBL] [Abstract][Full Text] [Related]
8. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition.
Jiang L; Oldenburg E; Kromann-Hansen T; Xu P; Jensen JK; Andreasen PA; Huang M
Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2017-2023. PubMed ID: 29959058
[TBL] [Abstract][Full Text] [Related]
9. Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action.
Roodbeen R; Paaske B; Jiang L; Jensen JK; Christensen A; Nielsen JT; Huang M; Mulder FA; Nielsen NC; Andreasen PA; Jensen KJ
Chembiochem; 2013 Nov; 14(16):2179-88. PubMed ID: 24115455
[TBL] [Abstract][Full Text] [Related]
10. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
11. Phage selection of cyclic peptide antagonists with increased stability toward intestinal proteases.
Baeriswyl V; Heinis C
Protein Eng Des Sel; 2013 Jan; 26(1):81-9. PubMed ID: 23100545
[TBL] [Abstract][Full Text] [Related]
12. Interconversion of active and inactive conformations of urokinase-type plasminogen activator.
Liu Z; Kromann-Hansen T; Lund IK; Hosseini M; Jensen KJ; Høyer-Hansen G; Andreasen PA; Sørensen HP
Biochemistry; 2012 Oct; 51(39):7804-11. PubMed ID: 22950516
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus.
Frecer V; Kabelác M; De Nardi P; Pricl S; Miertus S
J Mol Graph Model; 2004 Jan; 22(3):209-20. PubMed ID: 14629979
[TBL] [Abstract][Full Text] [Related]
14. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.
Jiang L; Andersen LM; Andreasen PA; Chen L; Huang M
Biochim Biophys Acta; 2016 Mar; 1860(3):599-606. PubMed ID: 26691138
[TBL] [Abstract][Full Text] [Related]
15. Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors.
Xu P; Andreasen PA; Huang M
Int J Biol Sci; 2017; 13(10):1222-1233. PubMed ID: 29104489
[TBL] [Abstract][Full Text] [Related]
16. Improving binding affinity and stability of peptide ligands by substituting glycines with D-amino acids.
Chen S; Gfeller D; Buth SA; Michielin O; Leiman PG; Heinis C
Chembiochem; 2013 Jul; 14(11):1316-22. PubMed ID: 23828687
[TBL] [Abstract][Full Text] [Related]
17. Binding of nonphysiological protein and peptide substrates to proteases: differences between urokinase-type plasminogen activator and trypsin and contributions to the evolution of regulated proteolysis.
Bergstrom RC; Coombs GS; Ye S; Madison EL; Goldsmith EJ; Corey DR
Biochemistry; 2003 May; 42(18):5395-402. PubMed ID: 12731881
[TBL] [Abstract][Full Text] [Related]
18. Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor.
Xu P; Xu M; Jiang L; Yang Q; Luo Z; Dauter Z; Huang M; Andreasen PA
J Med Chem; 2015 Nov; 58(22):8868-76. PubMed ID: 26536069
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
20. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases.
Xue G; Xie X; Zhou Y; Yuan C; Huang M; Jiang L
Biosci Biotechnol Biochem; 2020 Jun; 84(6):1153-1159. PubMed ID: 32019421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
